NASDAQ:OPT Opthea (OPT) Stock Price, News & Analysis $3.41 0.00 (0.00%) As of 03/28/2025 Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Opthea Stock (NASDAQ:OPT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Opthea alerts:Sign Up Key Stats Today's Range$3.41▼$3.4150-Day Range$3.07▼$5.9252-Week Range$1.79▼$6.30VolumeN/AAverage Volume26,061 shsMarket Capitalization$524.84 millionP/E RatioN/ADividend YieldN/APrice Target$1.33Consensus RatingHold Company OverviewOpthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead product candidate is Sozinibercept (OPT 302), a soluble form of vascular endothelial growth factor receptor-3 VEGFR-3, currently under Phase 3 clinical development as a novel therapy for wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.Read More… Remove Ads Opthea Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks14th Percentile Overall ScoreOPT MarketRank™: Opthea scored higher than 14% of companies evaluated by MarketBeat, and ranked 902nd out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.1 / 5Analyst RatingHold Consensus RatingOpthea has received a consensus rating of Hold. The company's average rating score is 2.17, and is based on no buy ratings, 4 hold ratings, and 1 sell rating.Amount of Analyst CoverageOpthea has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Opthea's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Opthea are expected to grow in the coming year, from ($1.39) to ($0.67) per share. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted0.35% of the float of Opthea has been sold short.Short Interest Ratio / Days to CoverOpthea has a short interest ratio ("days to cover") of 16.5, which indicates bearish sentiment.Change versus previous monthShort interest in Opthea has recently increased by 20.66%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOpthea does not currently pay a dividend.Dividend GrowthOpthea does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.35% of the float of Opthea has been sold short.Short Interest Ratio / Days to CoverOpthea has a short interest ratio ("days to cover") of 16.5, which indicates bearish sentiment.Change versus previous monthShort interest in Opthea has recently increased by 20.66%, indicating that investor sentiment is decreasing significantly. News and Social Media1.5 / 5News Sentiment-0.38 News SentimentOpthea has a news sentiment score of -0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.80 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 43 news articles for Opthea this week, compared to 3 articles on an average week.MarketBeat Follows4 people have added Opthea to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Opthea insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.20% of the stock of Opthea is held by insiders.Percentage Held by Institutions55.95% of the stock of Opthea is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Opthea's insider trading history. Receive OPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Opthea and its competitors with MarketBeat's FREE daily newsletter. Email Address OPT Stock News HeadlinesFY2025 EPS Estimates for Opthea Reduced by Leerink PartnrsMarch 29 at 2:05 AM | americanbankingnews.comOpthea Limited (NASDAQ:OPT) Receives $1.33 Average Target Price from BrokeragesMarch 29 at 1:05 AM | americanbankingnews.comNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Washington. Its purpose: to put Donald Trump’s face on the $100 note. All to celebrate a new “golden age” for America. March 30, 2025 | Paradigm Press (Ad)HotCopper Highlights for Week 13 – Opthea, Reject Shop, Bellevue & more!March 28 at 2:58 AM | msn.comThe clinical trial result from hell has biotech investors on edgeMarch 28 at 2:58 AM | afr.comWhat is HC Wainwright's Forecast for Opthea FY2025 Earnings?March 28 at 1:45 AM | americanbankingnews.comPengana freezes fund redemptions as it braces for big Opthea lossMarch 27 at 4:40 AM | afr.comOpthea (NASDAQ:OPT) Downgraded to Hold Rating by Leerink PartnrsMarch 27 at 3:19 AM | americanbankingnews.comSee More Headlines OPT Stock Analysis - Frequently Asked Questions How have OPT shares performed this year? Opthea's stock was trading at $3.93 at the beginning of 2025. Since then, OPT shares have decreased by 13.2% and is now trading at $3.41. View the best growth stocks for 2025 here. When did Opthea IPO? Opthea (OPT) raised $161 million in an IPO on Friday, October 16th 2020. The company issued 9,300,000 shares at a price of $17.26 per share. Citigroup and SVB Leerink acted as the underwriters for the IPO and Oppenheimer & Co. and Truist Securities were co-managers. Who are Opthea's major shareholders? Opthea's top institutional shareholders include Hsbc Holdings PLC (0.10%), Millennium Management LLC (0.04%), Citadel Advisors LLC (0.01%) and OLD Mission Capital LLC (0.01%). How do I buy shares of Opthea? Shares of OPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Opthea own? Based on aggregate information from My MarketBeat watchlists, some other companies that Opthea investors own include PayPal (PYPL), Sunrun (RUN), Avino Silver & Gold Mines (ASM), Avino Silver & Gold Mines (ASM), QUALCOMM (QCOM), Ross Stores (ROST) and Zendesk (ZEN). Company Calendar Today3/29/2025Fiscal Year End6/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:OPT CIK1815620 Webwww.opthea.com Phone61-3-9826-0399FaxN/AEmployees8Year FoundedN/APrice Target and Rating Average Stock Price Target$1.33 High Stock Price Target$2.00 Low Stock Price Target$1.00 Potential Upside/Downside-60.9%Consensus RatingHold Rating Score (0-4)2.17 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio2.94 Quick Ratio2.94 Sales & Book Value Annual Sales$87,666.00 Price / Sales5,986.77 Cash FlowN/A Price / Cash FlowN/A Book Value($0.56) per share Price / Book-6.09Miscellaneous Outstanding Shares153,911,000Free Float148,981,000Market Cap$524.84 million OptionableNot Optionable Beta1.12 (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:OPT) was last updated on 3/30/2025 by MarketBeat.com Staff From Our PartnersTrump's 100-Day Plan Triggers Global RetaliationIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredWall Street’s “AI Oracle” Reveals Next Big Tech PlayA tiny American tech company could be at the center of the next big AI breakthrough. Wall Street's "AI Orac...InvestorPlace | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredCrypto Genius: 12,000% in 12 months? [Here’s how]We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredThe Dirty Secret About Gold Mining Stocks...Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy sharehold...Golden Portfolio | SponsoredForget Trump’s Tariffs, This March Event Is BiggerWhile everyone is distracted by Trump’s tariffs and a potential trade war… There’s something much bigger ha...Brownstone Research | SponsoredTermination: 18F (read immediately)Have you ever heard of the government's 18F program? It helped manage digital services across the governmen...Altimetry | SponsoredDoomed: These 50 Stocks Will Die Under Trump’s MAGA policies.Remember Kodak? Sears? Circuit City? They all failed to adapt to the changing times. Now, history is abo...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Opthea Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Opthea With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.